2025-523921-17-00RecruitingPhase 2
Interleukin-1 inhibition to improve the response of myeloproliferative neoplasms resistant to cytoreductive treatment
Centre Hospitalier Regional Et Universitaire De Brest5 sites in 1 country50 target enrollmentStarted: June 1, 2026Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Status
- Recruiting
- Enrollment
- 50
- Locations
- 5
- Primary Endpoint
- Baseline and 3-month serum calprotectin levels.
Study Overview
Brief Summary
To demonstrate a decrease in serum calprotectin levels at 3 months in the anakinra arm compared with the standard of care.
Eligibility Criteria
- Ages
- 18 years to 65+ years (18-64 Years, 65+ Years)
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Diagnosis of MPN: PV, ET, or PMF according to WHO criteria
- •Stable cytoreductive therapy for at least 6 months
- •Incomplete hematologic response according to ELN criteria, excluding bone marrow, OR complete hematologic response with anemia in ET, OR persistence of general clinical symptoms (fever, night sweats, pruritus, fatigue > 5/10 on VAS)
- •Adult patient capable of providing informed consent
Exclusion Criteria
- •Recurrent or poorly controlled infections
- •Lack of understanding of questionnaires or inability to follow up.
- •Women of childbearing potential unwilling to use appropriate contraception.
- •Thrombocytopenia < 100 G/L
- •Neutropenia < 1 G/L
- •Hypersensitivity to the active substance, any excipients, or proteins derived from Escherichia coli
- •Concomitant immunosuppressive therapy
- •Refusal to participate
- •Patient under legal protection (guardianship, curatorship, etc.)
- •Patients unable to consent.
- •Pregnant or breastfeeding women.
Arms & Interventions
Kineret 100 mg/0.67 ml solution for injection in pre-filled syringe.
Test
Intervention: Kineret 100 mg/0.67 ml solution for injection in pre-filled syringe. (Drug)
Outcomes
Primary Outcomes
Baseline and 3-month serum calprotectin levels.
Baseline and 3-month serum calprotectin levels.
Secondary Outcomes
- - Multiplex assay of inflammatory cytokines at baseline, 3 and 6 months
- - Improvement (yes/no) of the response statusresponse status (according to ELN criteria) between baseline-M3, baseline-M6, M3-M6
- - hematological parameters (e.g., hemoglobin, hematocrit, white blood cell count, platelet count) at baseline, 3 and 6 months..
- - Patient-reported symptom severity over the previous 4 weeks assessed using a 10-point Visual Analog Scale (VAS) for pruritus, fever, and night sweats at baseline, 3 and 6 months.
- - Treatment-related adverse events (type and number)
- - Daily self-reported treatment intake (Yes/No) recorded in the patient diary over the 3-month period
- - EORTC QLQ-C30 score at baseline, 3 and 6 months
- - Quantification of JAK2V617F, CALR exon 9, or MPL W515 at baseline, 3 and 6 months
- - Measurement of circulating CD34+ cells at baseline, 3 and 6 months
Investigators
DOLOU Julien
Scientific
Centre Hospitalier Regional Et Universitaire De Brest
Study Sites (5)
Loading locations...
Similar Trials
Not yet recruiting
Phase 2
Targeting inflammation to reduce 90-day and 1-year postoperative severe morbidity in patients with unfavorable inflammatory profile undergoing oncologic surgery (POST CARE Trial)2024-515333-14-03Fondazione IRCCS Istituto Nazionale Dei Tumori83
Recruiting
Phase 2
Targeted therapy with anakinra for dilated cardiomyopathy: phase IIa randomized double blind monocentric clinical trial to evaluate the efficacy and safety of anakinra plus standard of care vs standard of care alone in the treatment of dilated cardiomyopathy.2024-514861-21-00Ospedale San Raffaele S.r.l.24
Recruiting
Phase 2
Myocarditis Therapy with IL-1 inhibitor (MYTH-1): a double-blind, phase IIa, placebo-controlled, randomized clinical trial to evaluate the efficacy and safety of anakinra in addition to standard of care for the treatment of virus-negative myocarditis2024-515472-13-00Ospedale San Raffaele S.r.l., Ospedale San Raffaele S.r.l.32
Recruiting
Phase 2
THRILL: Treat Hyperinflammation in child oncology studySepsis2025-524541-27-00Prinses Maxima Centrum voor Kinderoncologie B.V.76
Not yet recruiting
Not Applicable
Role of combination of Marich and Goghrit in Patients Suffering from SheetpittaCTRI/2026/01/100522Dr Shweta Chandrashekhar Moon60